A Randomized, Double-blind, Triple-dummy, Dose-ranging Study, Including an Active Control of Unfractionated Heparin and Eptifibatide, to Evaluate the Clinical Efficacy and Safety of Otamixaban, in Patients With Non-ST Elevation Acute Coronary Syndrome and Planned Early Invasive Strategy.

Trial Profile

A Randomized, Double-blind, Triple-dummy, Dose-ranging Study, Including an Active Control of Unfractionated Heparin and Eptifibatide, to Evaluate the Clinical Efficacy and Safety of Otamixaban, in Patients With Non-ST Elevation Acute Coronary Syndrome and Planned Early Invasive Strategy.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2014

At a glance

  • Drugs Otamixaban (Primary) ; Eptifibatide; Heparin
  • Indications Acute coronary syndromes; Embolism and thrombosis
  • Focus Therapeutic Use
  • Acronyms SEPIA-ACS1-TIMI-42
  • Sponsors Sanofi
  • Most Recent Events

    • 30 Aug 2009 Results presented at ESC 2009.
    • 30 Aug 2009 Results were published in the Lancet.
    • 07 Jul 2009 Additional trial locations added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top